A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

Inclusion Criteria: * Must be able to understand a written informed consent, which must be obtained prior to initiation of study procedures. * Must be willing and able to comply with all study requirements. * Healthy males or non-pregnant, non-lactating healthy females. * Aged 18 to 50 years of age (inclusive) at the time of signing informed consent. * BMI of 18.0 kg/m\^2 to 30.0 kg/m\^2 (inclusive) as measured at Screening. * Women of childbearing potential who are sexually active with a male partner must practice effective contraception during the study treatment period and for 90 days after last IMP administration. They must agree to use 2 different means of nonhormonal contraceptive methods. * Women of non-childbearing potential must be either surgically sterile or in menopausal state confirmed as follows: 1 year of spontaneous amenorrhea without an alternative medical cause and a serum follicle stimulating hormone (FSH) level ≥40 mIU/mL. * Male participants who are sexually active with a female partner of childbearing potential must use, with their partner, a condom plus an approved method of highly effective contraception from the time of informed consent until 90 days after last IMP administration. * Women should not donate eggs and men should not donate sperm during the study treatment period and for at least 90 days after last IMP administration. * All female participants must have a negative serum pregnancy test at Screening and Admission (Day -2). Exclusion Crite…